Cancer risk in severe alpha-1-antitrypsin deficiency: the importance of early identification
(2022) In European Respiratory Journal 60(5).- Abstract
Background Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is a risk factor for pulmonary emphysema and liver disease, but its effect on cancer risk is unknown. Our aim was to evaluate the risk and the risk factors for incident cancer in PiZZ individuals compared with the general population with known smoking habits. Methods A longitudinal study of PiZZ individuals (n=1,595) from the Swedish National AATD Register, and controls (n=5,999) from Swedish population-based cohorts. Data on cancer and mortality were obtained by cross-linkage with national registers. Individuals who had undergone lung transplantation (n=10) and those with a cancer diagnosis within five years prior to inclusion (n=63) were excluded. The risk... (More)
Background Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is a risk factor for pulmonary emphysema and liver disease, but its effect on cancer risk is unknown. Our aim was to evaluate the risk and the risk factors for incident cancer in PiZZ individuals compared with the general population with known smoking habits. Methods A longitudinal study of PiZZ individuals (n=1,595) from the Swedish National AATD Register, and controls (n=5,999) from Swedish population-based cohorts. Data on cancer and mortality were obtained by cross-linkage with national registers. Individuals who had undergone lung transplantation (n=10) and those with a cancer diagnosis within five years prior to inclusion (n=63) were excluded. The risk factors for developing cancer were analyzed using proportional hazards and Fine-Gray regression models, adjusting for age, sex, smoking habits and the presence of liver disease. Results The median follow-up time was 17 years (IQR 11) for the whole study population. The incidence rate of hepatic and non-hepatic cancer per 1,000 person-years was 1.6 (95% CI 1.1-2.3) and 8.5 (95% CI 7.2-10.0) for the PiZZ individuals, and 0.1 (95% CI 0.04-0.2) and 6.6 (95% CI 6.0-7.1) for the controls, respectively. The adjusted hazard ratios (HR) for hepatic and for non-hepatic cancer were 23.4 (95% CI 9.9-55.4) and 1.3 (95% CI 1.1-1.5) respectively, in the PiZZ individuals compared with the controls. Conclusion These results suggest that individuals with severe alpha-1-antitrypsin deficiency may have an increased risk of developing both hepatic and non-hepatic cancer, compared with the general population.
(Less)
- author
- Hiller, Adriana Maria LU ; Ekström, Magnus LU ; Piitulainen, Eeva LU ; Lindberg, Anne ; Rönmark, Eva and Tanash, Hanan LU
- organization
-
- Respiratory Medicine, Allergology, and Palliative Medicine
- Alpha-1-antitrypsin deficiency (research group)
- Internal Medicine - Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- Breathlessness and chronic respiratory failure (research group)
- The Institute for Palliative Care (research group)
- publishing date
- 2022-11-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alpha-1-antitrypsin deficiency, cancer, hepatic cancer, risk factors, survival
- in
- European Respiratory Journal
- volume
- 60
- issue
- 5
- article number
- 2200846
- publisher
- European Respiratory Society
- external identifiers
-
- pmid:35361631
- scopus:85141646715
- ISSN
- 0903-1936
- DOI
- 10.1183/13993003.00846-2022
- language
- English
- LU publication?
- yes
- id
- 678d73bc-35b1-4154-b2a1-aaea42331490
- date added to LUP
- 2022-12-01 14:47:04
- date last changed
- 2024-11-01 00:29:44
@article{678d73bc-35b1-4154-b2a1-aaea42331490, abstract = {{<p>Background Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is a risk factor for pulmonary emphysema and liver disease, but its effect on cancer risk is unknown. Our aim was to evaluate the risk and the risk factors for incident cancer in PiZZ individuals compared with the general population with known smoking habits. Methods A longitudinal study of PiZZ individuals (n=1,595) from the Swedish National AATD Register, and controls (n=5,999) from Swedish population-based cohorts. Data on cancer and mortality were obtained by cross-linkage with national registers. Individuals who had undergone lung transplantation (n=10) and those with a cancer diagnosis within five years prior to inclusion (n=63) were excluded. The risk factors for developing cancer were analyzed using proportional hazards and Fine-Gray regression models, adjusting for age, sex, smoking habits and the presence of liver disease. Results The median follow-up time was 17 years (IQR 11) for the whole study population. The incidence rate of hepatic and non-hepatic cancer per 1,000 person-years was 1.6 (95% CI 1.1-2.3) and 8.5 (95% CI 7.2-10.0) for the PiZZ individuals, and 0.1 (95% CI 0.04-0.2) and 6.6 (95% CI 6.0-7.1) for the controls, respectively. The adjusted hazard ratios (HR) for hepatic and for non-hepatic cancer were 23.4 (95% CI 9.9-55.4) and 1.3 (95% CI 1.1-1.5) respectively, in the PiZZ individuals compared with the controls. Conclusion These results suggest that individuals with severe alpha-1-antitrypsin deficiency may have an increased risk of developing both hepatic and non-hepatic cancer, compared with the general population.</p>}}, author = {{Hiller, Adriana Maria and Ekström, Magnus and Piitulainen, Eeva and Lindberg, Anne and Rönmark, Eva and Tanash, Hanan}}, issn = {{0903-1936}}, keywords = {{Alpha-1-antitrypsin deficiency; cancer; hepatic cancer; risk factors; survival}}, language = {{eng}}, month = {{11}}, number = {{5}}, publisher = {{European Respiratory Society}}, series = {{European Respiratory Journal}}, title = {{Cancer risk in severe alpha-1-antitrypsin deficiency: the importance of early identification}}, url = {{http://dx.doi.org/10.1183/13993003.00846-2022}}, doi = {{10.1183/13993003.00846-2022}}, volume = {{60}}, year = {{2022}}, }